Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Samsung Biologics (207940 KS): Starts 2026 with Double-Digit Revenue Growth; FY Guidance Reaffirmed

Samsung Biologics (207940 KS): Robust 2Q Result; New Acquisition to Expand Modality into Peptides

Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance

Samsung Biologics (207940 KS): Bumps up Full Year Guidance Amid Strong 2Q Show and Plant 4 Ramp-Up

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> achieved 2025 revenue of KRW4,557B, up 30% YoY. Consistent operations across the existing plants and successful ramp-up of Plant 4 aided the performance.</li>
<li>2025 annual order intake surpassed KRW6T mark, including three contracts valued at over KRW1T each. Cumulative contract value exceeded $21B, including 107 CMO projects and 164 for CDO projects.</li>
<li>Excluding potential contributions from the planned acquisition of the U.S. site, Samsung Biologics projected 15–20% annual revenue growth for 2026, with an estimated revenue figure of KRW5,240–5,468B.</li>
</ul>



Samsung Biologics (207940 KS) achieved 2025 revenue of KRW4,557B, up 30% YoY. Consistent operations across the existing plants and successful ramp-up of Plant 4 aided the performance.
2025 annual order intake surpassed KRW6T mark, including three contracts valued at over KRW1T each. Cumulative contract value exceeded $21B, including 107 CMO projects and 164 for CDO projects.
Excluding potential contributions from the planned acquisition of the U.S. site, Samsung Biologics projected 15–20% annual revenue growth for 2026, with an estimated revenue figure of KRW5,240–5,468B.


Samsung Biologics (207940 KS): 2025 Revenue Meet Guidance; Big Fat Order Book Lends Visibility Ahead